Schreiner MediPharm Partners with Packaging Manufacturer Edelmann
News Aug 20, 2015
In a joint project with packaging manufacturer Edelmann, Schreiner MediPharm has developed an innovative solution that makes important product information accessible on the exterior of folding cartons. The new solution, which eliminates the need for pharmacists or consumers to first open a package before obtaining detailed product information, meets related requirements of the EU Falsified Medicines Directive 2011/62/EU.
Among other measures, the EU directive requires a security seal for the outer or secondary packaging of medicines, in order to prevent risk of manipulations. With traditional packages, pharmacists can only read the package insert after destroying the seal, which is meant to form a barrier and serve as a first-opening indication.
To eliminate the need for the package’s opening, Schreiner MediPharm worked with Germany-based Edelmann, a leading supplier of folding boxes, to create a novel solution combining a folding box with a Booklet-Label applied to the outside.
Applied to the outer packaging, the multi-page Booklet-Label from Schreiner MediPharm makes even multi-lingual product information easily accessible and readily visible without damaging the original package. It reliably adheres to folding cartons and is easy to open and close again via a top layer of film that serves as a cover. The Booklet-Label also is equipped with a security color-shifting ink for integrated protection against counterfeiting.
“The solution that has been jointly developed with Edelmann maintains the integrity of the folding carton while allowing easy access to the package insert,” said Gene Dul, President of Schreiner MediPharm U.S. “In addition to helping pharmacists comply with new regulations, the Booklet-Label also benefits consumers. Since the booklet is firmly attached to the package, it is less likely to be misplaced.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE